Spinal Cord Stimulation and Small Fiber Peripheral Neuropathy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorOhio State University

About this trial

This is a prospective randomized control trial. Participants enrolled into the study will be randomized into one of three groups, two of which are treatment groups and the third is a control group. A time course of measurements before and after spinal cord stimulation (SCS) treatment (where applicable) will assess pain, DPN severity, small fiber nerve activity, and metabolic health markers.

Eligibility criteria

Qualifiers

Over 18 years old

Diagnosis of diabetic peripheral neuropathy refractory to treatment with gabapentin or pregabalin and at least 1 other class of analgesic

Diagnosis of medically refractory pain secondary to diabetic neuropathy

Presence of pain for 12 months

Disqualifiers

Severe medical comorbidities that, in the opinion of the surgeon, exclude the patient from surgical intervention

Spinal disease with severe spinal stenosis or spinal cord compression in the region of the proposed spinal cord stimulator lead placement

Coagulopathy that cannot be corrected

Unable to discontinue blood thinning medications

Trial design

Treatments tested in this trial

  • Spinal Cord Stimulator Implantation (SCS)

Treatment groups

60 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Ohio State University

Lead sponsor

Neuright, Inc.

Collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Collaborator